363P 在大型临床中心和登记处使用 PUL 2.0 对杜氏肌营养不良症患者的上肢功能进行横断面调查

IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Neuromuscular Disorders Pub Date : 2024-10-01 DOI:10.1016/j.nmd.2024.07.100
G. Coratti , E. Niks , M. van der Holst , C. Tian , E. Mercuri , F. Muntoni , L. Servais , S. Ward
{"title":"363P 在大型临床中心和登记处使用 PUL 2.0 对杜氏肌营养不良症患者的上肢功能进行横断面调查","authors":"G. Coratti ,&nbsp;E. Niks ,&nbsp;M. van der Holst ,&nbsp;C. Tian ,&nbsp;E. Mercuri ,&nbsp;F. Muntoni ,&nbsp;L. Servais ,&nbsp;S. Ward","doi":"10.1016/j.nmd.2024.07.100","DOIUrl":null,"url":null,"abstract":"<div><div>Upper limb function is a critical determinant of quality of life for patients with Duchenne Muscular Dystrophy (DMD) who have lost the ability to walk. However, the majority of clinical trials assessing new therapeutic agents have focused on ambulant patients with DMD. The reasons for this gap are multi-fold but are due in part to the consensus for using the PUL 2.0 assessment as a primary endpoint being more recent. This study is a cross-functional survey of upper limb functional assessments focused on the large clinical centers and clinical registries led by cTAP collaborators and determined i) the number of patients with PUL 2.0 assessments, ii) frequency of evaluation, iii) functional characteristics of patients at baseline, and iv) the trigger for initiating PUL 2.0 evaluation. Most centers assessed upper limb function at 6-month intervals. The number of patients and patient visits at each center were, respectively: Italian Group (341,1628), CCHMC (256, 1145), GOSH (84, ∼240), Leiden University Medical Center (LUMC)(81, 278) and NMCL (25, &gt;100). Mean PUL 2.0 entry score was 29.9 (SD 12.5) and 30.93 (SD 5.1) in the Italian Group and LUMC respectively; corresponding age at entry was (12.2 (SD 6.23) and 11.75 (SD 12.1). The number of patients with 5 or more follow-up assessments was 88 at 6 monthly intervals for the Italian Group and 28 at 12-month intervals for LUMC. Assessment of ambulatory function across centers was largely coherent, while protocols to assess bone health, cardiac function, and pulmonary function were less consistent. The results of this study will aid drug developers in better understanding the characteristics of this patient population, a pre-requisite step to designing clinical trials that can yield definitive assessment and therapeutic efficacy. It also highlights the importance of collecting consistent and high-quality real-world data in rare diseases.</div></div>","PeriodicalId":19135,"journal":{"name":"Neuromuscular Disorders","volume":"43 ","pages":"Article 104441.91"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"363P A cross-sectional survey upper limb functional using PUL 2.0 at large clinical centers and registries in patients with Duchenne muscular dystrophy\",\"authors\":\"G. Coratti ,&nbsp;E. Niks ,&nbsp;M. van der Holst ,&nbsp;C. Tian ,&nbsp;E. Mercuri ,&nbsp;F. Muntoni ,&nbsp;L. Servais ,&nbsp;S. Ward\",\"doi\":\"10.1016/j.nmd.2024.07.100\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Upper limb function is a critical determinant of quality of life for patients with Duchenne Muscular Dystrophy (DMD) who have lost the ability to walk. However, the majority of clinical trials assessing new therapeutic agents have focused on ambulant patients with DMD. The reasons for this gap are multi-fold but are due in part to the consensus for using the PUL 2.0 assessment as a primary endpoint being more recent. This study is a cross-functional survey of upper limb functional assessments focused on the large clinical centers and clinical registries led by cTAP collaborators and determined i) the number of patients with PUL 2.0 assessments, ii) frequency of evaluation, iii) functional characteristics of patients at baseline, and iv) the trigger for initiating PUL 2.0 evaluation. Most centers assessed upper limb function at 6-month intervals. The number of patients and patient visits at each center were, respectively: Italian Group (341,1628), CCHMC (256, 1145), GOSH (84, ∼240), Leiden University Medical Center (LUMC)(81, 278) and NMCL (25, &gt;100). Mean PUL 2.0 entry score was 29.9 (SD 12.5) and 30.93 (SD 5.1) in the Italian Group and LUMC respectively; corresponding age at entry was (12.2 (SD 6.23) and 11.75 (SD 12.1). The number of patients with 5 or more follow-up assessments was 88 at 6 monthly intervals for the Italian Group and 28 at 12-month intervals for LUMC. Assessment of ambulatory function across centers was largely coherent, while protocols to assess bone health, cardiac function, and pulmonary function were less consistent. The results of this study will aid drug developers in better understanding the characteristics of this patient population, a pre-requisite step to designing clinical trials that can yield definitive assessment and therapeutic efficacy. It also highlights the importance of collecting consistent and high-quality real-world data in rare diseases.</div></div>\",\"PeriodicalId\":19135,\"journal\":{\"name\":\"Neuromuscular Disorders\",\"volume\":\"43 \",\"pages\":\"Article 104441.91\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuromuscular Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960896624002645\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuromuscular Disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960896624002645","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

对于丧失行走能力的杜兴氏肌肉萎缩症(DMD)患者来说,上肢功能是决定其生活质量的关键因素。然而,大多数评估新治疗药物的临床试验都集中在行动不便的 DMD 患者身上。造成这种差距的原因是多方面的,但部分原因是将 PUL 2.0 评估作为主要终点的共识是最近才达成的。本研究是一项关于上肢功能评估的跨职能调查,重点关注 cTAP 合作者领导的大型临床中心和临床登记处,并确定了 i) 进行 PUL 2.0 评估的患者人数;ii) 评估频率;iii) 基线时患者的功能特征;以及 iv) 启动 PUL 2.0 评估的触发因素。大多数中心每 6 个月评估一次上肢功能。各中心的患者人数和患者就诊次数分别为意大利集团(341,1628人次)、CCHMC(256,1145人次)、GOSH(84,240人次)、莱顿大学医学中心(81,278人次)和NMCL(25,100人次)。意大利组和 LUMC 的 PUL 2.0 平均入选分数分别为 29.9 (SD 12.5) 和 30.93 (SD 5.1);相应的入选年龄分别为 12.2 (SD 6.23) 和 11.75 (SD 12.1)。意大利小组中接受过 5 次或 5 次以上随访评估的患者人数为 88 人(每 6 个月一次),LUMC 为 28 人(每 12 个月一次)。各中心对活动功能的评估基本一致,而对骨骼健康、心脏功能和肺功能的评估方案则不太一致。这项研究的结果将有助于药物开发人员更好地了解这一患者群体的特征,这是设计临床试验的前提步骤,临床试验将产生明确的评估结果和疗效。它还强调了在罕见病领域收集一致且高质量的真实世界数据的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
363P A cross-sectional survey upper limb functional using PUL 2.0 at large clinical centers and registries in patients with Duchenne muscular dystrophy
Upper limb function is a critical determinant of quality of life for patients with Duchenne Muscular Dystrophy (DMD) who have lost the ability to walk. However, the majority of clinical trials assessing new therapeutic agents have focused on ambulant patients with DMD. The reasons for this gap are multi-fold but are due in part to the consensus for using the PUL 2.0 assessment as a primary endpoint being more recent. This study is a cross-functional survey of upper limb functional assessments focused on the large clinical centers and clinical registries led by cTAP collaborators and determined i) the number of patients with PUL 2.0 assessments, ii) frequency of evaluation, iii) functional characteristics of patients at baseline, and iv) the trigger for initiating PUL 2.0 evaluation. Most centers assessed upper limb function at 6-month intervals. The number of patients and patient visits at each center were, respectively: Italian Group (341,1628), CCHMC (256, 1145), GOSH (84, ∼240), Leiden University Medical Center (LUMC)(81, 278) and NMCL (25, >100). Mean PUL 2.0 entry score was 29.9 (SD 12.5) and 30.93 (SD 5.1) in the Italian Group and LUMC respectively; corresponding age at entry was (12.2 (SD 6.23) and 11.75 (SD 12.1). The number of patients with 5 or more follow-up assessments was 88 at 6 monthly intervals for the Italian Group and 28 at 12-month intervals for LUMC. Assessment of ambulatory function across centers was largely coherent, while protocols to assess bone health, cardiac function, and pulmonary function were less consistent. The results of this study will aid drug developers in better understanding the characteristics of this patient population, a pre-requisite step to designing clinical trials that can yield definitive assessment and therapeutic efficacy. It also highlights the importance of collecting consistent and high-quality real-world data in rare diseases.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuromuscular Disorders
Neuromuscular Disorders 医学-临床神经学
CiteScore
4.60
自引率
3.60%
发文量
543
审稿时长
53 days
期刊介绍: This international, multidisciplinary journal covers all aspects of neuromuscular disorders in childhood and adult life (including the muscular dystrophies, spinal muscular atrophies, hereditary neuropathies, congenital myopathies, myasthenias, myotonic syndromes, metabolic myopathies and inflammatory myopathies). The Editors welcome original articles from all areas of the field: • Clinical aspects, such as new clinical entities, case studies of interest, treatment, management and rehabilitation (including biomechanics, orthotic design and surgery). • Basic scientific studies of relevance to the clinical syndromes, including advances in the fields of molecular biology and genetics. • Studies of animal models relevant to the human diseases. The journal is aimed at a wide range of clinicians, pathologists, associated paramedical professionals and clinical and basic scientists with an interest in the study of neuromuscular disorders.
期刊最新文献
Respiratory function and evaluation in individuals with facioscapulohumeral muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking and Research Network Neuromyotonia in a 16-year-old female with dramatic improvement after IVIG therapy: Case report and literature review My second life with mechanical ventilation: A golden anniversary Editorial Board Publisher's Note
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1